Colfax Corporation Investor Day

Colfax Corporation Investor Day March 11, 2021

Forward Looking Statement & Non-GAAP Disclaimer These materials

include "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be characterized by terms such as "believe," "anticipate,"

"should," "would," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy," "targets,"

"aims," "seeks," "sees" and similar expressions. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to, statements regarding: the

intended separation of the FabTech and MedTech businesses; expected 2021 revenue and Adjusted EBITDA for FabTech and MedTech; long-term financial goals for FabTech and MedTech; the timing and method of the separation; the anticipated benefits of the

separation; the expected financial and operating performance of, and future opportunities for, each company following the separation; the tax treatment of the transaction; and the leadership of each company following the separation. These statements

are based on assumptions and assessments made by our management as of the date of this presentation in light of their experience and perception of historical trends, current conditions, expected future developments, strategy, outlook, goals and

other factors believed to be appropriate. Forward-looking statements are subject to a number of risks, uncertainties and assumptions that might cause actual results, developments and business decisions to differ materially from those expressed or

implied thereby, and are not guarantees of future performance or actual results. These factors include, among other things: the final approval of the separation by our board of directors; the uncertainty of obtaining regulatory approvals in

connection with the separation, including rulings from the Internal Revenue Service; the ability to successfully complete financing and other transactions on satisfactory terms, and other steps necessary to qualify the separation as a tax-free

transaction; the ability to satisfy the necessary closing conditions to complete the separation on a timely basis, or at all; our ability to successfully separate the two companies and realize the anticipated benefits of the separation; developments

related to the impact of the COVID-19 pandemic on the separation and the financial and operating performance of each company following the separation, including actions by governments, businesses and individuals in response to the pandemic, and

other impacts on our business and ability to execute business continuity plans; and our ability to manage and grow our business and to execute our business and growth strategies. The effects of the COVID-19 pandemic, including actions by

governments, businesses and individuals in response to the pandemic, may also give rise or contribute to or amplify the risks associated with many of these factors. The factors identified above are not exhaustive. We operate in a dynamic business

environment in which new risks may emerge frequently. Other unknown or unpredictable factors could also cause actual results, developments and business decisions to differ materially from those expressed or implied by the forward-looking statements.

Forward-looking statements should be construed in the light of such factors. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. Additional information regarding these and other

factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements is set forth in our public filings with the Securities Exchange Commission (the "SEC"), including our Annual

Report on Form 10-K for the year ended December 31, 2020 and our subsequent filings with the SEC. We do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, whether as a result of new information, future

developments or otherwise. Colfax has provided in this presentation certain financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These

non-GAAP financial measures include adjusted EBITDA (adjusted EBITA plus depreciation and other amortization), adjusted EBITDA margin, organic (core) sales growth, and free cash flow. Colfax also provides adjusted EBITDA, adjusted EBITDA margin,

organic (core) sales growth and free cash flow on a segment basis. Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, acquisition-related amortization and other non-cash

charges, European Union Medical Device Regulation ("MDR") and other costs, and strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the

same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) on a segment basis, where we exclude the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges

from segment operating income. Adjusted EBITDA represents Adjusted EBITA plus depreciation and other amortization. Core or organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations.

Decremental margin represents the change in Adjusted EBITDA divided by the change in net sales. Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment. These non-GAAP financial

measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur

with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of Colfax. Colfax management also believes that presenting these measures allows investors to view its

performance using the same measures that Colfax uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in

accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation. In this presentation, Colfax presents

forward-looking non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITA and Free Cash Flow on a segment basis. Colfax does not provide such outlook on a GAAP basis because changes in the items that Colfax excludes from GAAP to calculate such

measures can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Colfax's routine operating activities. Additionally, management does not forecast many of the excluded

items for internal use and therefore cannot create or rely on outlook done on a GAAP basis. 2Forward Looking Statement & Non-GAAP Disclaimer These materials include "forward-looking" statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Forward-looking statements may be characterized by terms such as "believe," "anticipate," "should," "would," "intend," "plan,"

"will," "expect," "estimate," "project," "positioned," "strategy," "targets," "aims," "seeks," "sees" and similar expressions.

All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to, statements regarding: the intended separation of the FabTech and MedTech businesses; expected 2021 revenue and

Adjusted EBITDA for FabTech and MedTech; long-term financial goals for FabTech and MedTech; the timing and method of the separation; the anticipated benefits of the separation; the expected financial and operating performance of, and future

opportunities for, each company following the separation; the tax treatment of the transaction; and the leadership of each company following the separation. These statements are based on assumptions and assessments made by our management as of the

date of this presentation in light of their experience and perception of historical trends, current conditions, expected future developments, strategy, outlook, goals and other factors believed to be appropriate. Forward-looking statements are

subject to a number of risks, uncertainties and assumptions that might cause actual results, developments and business decisions to differ materially from those expressed or implied thereby, and are not guarantees of future performance or actual

results. These factors include, among other things: the final approval of the separation by our board of directors; the uncertainty of obtaining regulatory approvals in connection with the separation, including rulings from the Internal Revenue

Service; the ability to successfully complete financing and other transactions on satisfactory terms, and other steps necessary to qualify the separation as a tax-free transaction; the ability to satisfy the necessary closing conditions to complete

the separation on a timely basis, or at all; our ability to successfully separate the two companies and realize the anticipated benefits of the separation; developments related to the impact of the COVID-19 pandemic on the separation and the

financial and operating performance of each company following the separation, including actions by governments, businesses and individuals in response to the pandemic, and other impacts on our business and ability to execute business continuity

plans; and our ability to manage and grow our business and to execute our business and growth strategies. The effects of the COVID-19 pandemic, including actions by governments, businesses and individuals in response to the pandemic, may also give

rise or contribute to or amplify the risks associated with many of these factors. The factors identified above are not exhaustive. We operate in a dynamic business environment in which new risks may emerge frequently. Other unknown or unpredictable

factors could also cause actual results, developments and business decisions to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements should be construed in the light of such factors. Readers

are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. Additional information regarding these and other factors that may cause actual results to differ materially from those expressed or

implied by the forward-looking statements is set forth in our public filings with the Securities Exchange Commission (the "SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2020 and our subsequent filings

with the SEC. We do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise. Colfax has provided in this presentation certain financial

information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures include adjusted EBITDA (adjusted EBITA plus depreciation

and other amortization), adjusted EBITDA margin, organic (core) sales growth, and free cash flow. Colfax also provides adjusted EBITDA, adjusted EBITDA margin, organic (core) sales growth and free cash flow on a segment basis. Adjusted EBITA

represents net income (loss) from continuing operations excluding restructuring and other related charges, acquisition-related amortization and other non-cash charges, European Union Medical Device Regulation ("MDR") and other costs, and

strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted

EBITA margin) on a segment basis, where we exclude the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income. Adjusted EBITDA represents Adjusted EBITA plus

depreciation and other amortization. Core or organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations. Decremental margin represents the change in Adjusted EBITDA divided by the change

in net sales. Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment. These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because

certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally

different from the ongoing productivity improvements of Colfax. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that Colfax uses in evaluating its financial and business

performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP

measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation. In this presentation, Colfax presents forward-looking non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITA and Free Cash Flow on

a segment basis. Colfax does not provide such outlook on a GAAP basis because changes in the items that Colfax excludes from GAAP to calculate such measures can be dependent on future events that are less capable of being controlled or reliably

predicted by management and are not part of Colfax's routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.

Agenda Q&A Logistics Mitch Rales 9:00 AM Chairman's

Introduction Ask questions by clicking submit Matt Trerotola Colfax Capabilities, Strategic Direction 9:20 AM question, next to presenter box within the meeting 9:40 AM Q&A 10:00 AM Shyam Kambeyanda ESAB Strategy, Progress, Opportunities

Olivier Biebuyck Kevin Johnson 10:45 AM Q&A 11:00 AM Break MedTechCo Strategy, Progress, Matt Trerotola 11:15 AM Opportunities Brady Shirley Louie Vogt Steve Ingel Once submitted, questions will Ben Berry remain in the queue 12:15 PM

Q&A 12:30 PM Colfax Financial Update & Wrap-Up Chris Hix 12:45 PM Q&A 3Agenda Q&A Logistics Mitch Rales 9:00 AM Chairman's Introduction Ask questions by clicking submit Matt Trerotola Colfax Capabilities, Strategic

Direction 9:20 AM question, next to presenter box within the meeting 9:40 AM Q&A 10:00 AM Shyam Kambeyanda ESAB Strategy, Progress, Opportunities Olivier Biebuyck Kevin Johnson 10:45 AM Q&A 11:00 AM Break MedTechCo Strategy, Progress, Matt

Trerotola 11:15 AM Opportunities Brady Shirley Louie Vogt Steve Ingel Once submitted, questions will Ben Berry remain in the queue 12:15 PM Q&A 12:30 PM Colfax Financial Update & Wrap-Up Chris Hix 12:45 PM Q&A 3

Chairman's Introduction - Mitch Rales 4Chairman's

Introduction - Mitch Rales 4

Separation Overview th Announced on March 4 the intent to separate into

two independent, publicly traded companies (completion targeted in the first quarter 2022) Creates focused specialty Medical Technologies and Fabrication Technology companies, positioning both to accelerate strategic momentum Enables each company to

sharpen its strategic focus to capitalize on distinct investment opportunities Allows each to be valued based on distinct strategic, operational and financial characteristics Now is the right time to build on the momentum in both businesses

5Separation Overview th Announced on March 4 the intent to separate into two independent, publicly traded companies (completion targeted in the first quarter 2022) Creates focused specialty Medical Technologies and Fabrication Technology companies,

positioning both to accelerate strategic momentum Enables each company to sharpen its strategic focus to capitalize on distinct investment opportunities Allows each to be valued based on distinct strategic, operational and financial characteristics

Now is the right time to build on the momentum in both businesses 5

Re-Shaped Portfolio for Maximum Value Creation 2017-2019 Transformation

2019-2020 Momentum 2021 - Future Portfolio changes Strengthened talent, accelerated Leaders in attractive, growing MedTech capabilities markets Created outperforming FabTech business Invested in innovation and

Sustainable business models for strategic acquisitions compounding value creation 1 $3.5B sales $3B+ Specialty MedTechCo with FabTech MedTech HSD Growth, Capital Allocation (ESAB) (DJO) Focused on Growth $3B+ FabTech Leader with MSD FabTech

Divested Growth, Balanced Capital Businesses (ESAB) Allocation 2017 2019 Businesses are Ready to be Independent, Publicly-Traded Companies 6 1 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019Re-Shaped Portfolio

for Maximum Value Creation 2017-2019 Transformation 2019-2020 Momentum 2021 - Future Portfolio changes Strengthened talent, accelerated Leaders in attractive, growing MedTech capabilities markets Created outperforming

FabTech business Invested in innovation and Sustainable business models for strategic acquisitions compounding value creation 1 $3.5B sales $3B+ Specialty MedTechCo with FabTech MedTech HSD Growth, Capital Allocation (ESAB) (DJO)

Focused on Growth $3B+ FabTech Leader with MSD FabTech Divested Growth, Balanced Capital Businesses (ESAB) Allocation 2017 2019 Businesses are Ready to be Independent, Publicly-Traded Companies 6 1 2019 shown pro forma to include periods prior to

DJO acquisition on February 22, 2019

Two Great Companies, Well-Positioned for Success Global Fabrication

Technology Leader Specialty Medical Technology Innovator MedTechCo >$30B market, global GDP + accelerators >$50B market, healthcare growth drivers Global leader with scale in all regions Focused in attractive

segments Strong brands and innovation engine Strong brands, innovation building Automating industrial workflows Automating clinic workflows Key Peers MedTech MidCaps Ortho Leaders FabTech Leaders Ossur Stryker Lincoln

Electric Conmed Zimmer Biomet ITW - Miller Teleflex Wright Medical* Large, Attractive Markets Great Opportunities for Profitable Growth 7 * Recently acquired by StrykerTwo Great Companies, Well-Positioned for Success Global Fabrication Technology

Leader Specialty Medical Technology Innovator MedTechCo >$30B market, global GDP + accelerators >$50B market, healthcare growth drivers Global leader with scale in all regions Focused in attractive segments

Strong brands and innovation engine Strong brands, innovation building Automating industrial workflows Automating clinic workflows Key Peers MedTech MidCaps Ortho Leaders FabTech Leaders Ossur Stryker Lincoln Electric

Conmed Zimmer Biomet ITW - Miller Teleflex Wright Medical* Large, Attractive Markets Great Opportunities for Profitable Growth 7 * Recently acquired by Stryker

Colfax Sustainable Model for Compounding Value Creation Talent

Above-Market Sales Growth CBS / Continuous Improvement Compounding Margin Expansion Value Creation Innovation Healthy Free Cash Flow Acquisitions / Portfolio Shaping Each Business now has these Core Capabilities to Drive Superior Performance 8Colfax

Sustainable Model for Compounding Value Creation Talent Above-Market Sales Growth CBS / Continuous Improvement Compounding Margin Expansion Value Creation Innovation Healthy Free Cash Flow Acquisitions / Portfolio Shaping Each Business now has these

Core Capabilities to Drive Superior Performance 8

Strong Cultures and Talent Processes Our Talent Imperatives Our Culture

Outstanding Talent 1 CBS-capable GMs and ops leaders; business-minded functional leads Full Bench 2 Depth & breadth for growth including acquisition integration Right Organization 3 Aligned for optimal performance & appropriately

incentivized Engaged, Diverse, Inclusive 4 Motivated, developed, challenged, and supported Culture and Talent are Critical to Executing our Strategy to Compound Value 9Strong Cultures and Talent Processes Our Talent Imperatives Our Culture

Outstanding Talent 1 CBS-capable GMs and ops leaders; business-minded functional leads Full Bench 2 Depth & breadth for growth including acquisition integration Right Organization 3 Aligned for optimal performance & appropriately